TWI641602B - 單環吡啶衍生物 - Google Patents

單環吡啶衍生物 Download PDF

Info

Publication number
TWI641602B
TWI641602B TW103105419A TW103105419A TWI641602B TW I641602 B TWI641602 B TW I641602B TW 103105419 A TW103105419 A TW 103105419A TW 103105419 A TW103105419 A TW 103105419A TW I641602 B TWI641602 B TW I641602B
Authority
TW
Taiwan
Prior art keywords
compound
mmol
mixture
ethyl acetate
added
Prior art date
Application number
TW103105419A
Other languages
English (en)
Chinese (zh)
Other versions
TW201439085A (zh
Inventor
船阪勢津雄
Setsuo Funasaka
岡田聰美
Toshimi Okada
田中圭悟
Keigo Tanaka
永尾聰
Satoshi Nagao
大橋功
Isao Ohashi
山根義伸
Yoshinobu Yamane
中谷祐介
Yusuke Nakatani
唐牛夕輝
Yuki Karoji
Original Assignee
衛材Ｒ＆Ｄ企管股份有限公司
Eisai R&D Management Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 衛材Ｒ＆Ｄ企管股份有限公司, Eisai R&D Management Co., Ltd. filed Critical 衛材Ｒ＆Ｄ企管股份有限公司
Publication of TW201439085A publication Critical patent/TW201439085A/zh
Application granted granted Critical
Publication of TWI641602B publication Critical patent/TWI641602B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
TW103105419A 2013-02-20 2014-02-18 單環吡啶衍生物 TWI641602B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361766922P 2013-02-20 2013-02-20
US61/766,922 2013-02-20

Publications (2)

Publication Number Publication Date
TW201439085A TW201439085A (zh) 2014-10-16
TWI641602B true TWI641602B (zh) 2018-11-21

Family

ID=51351646

Family Applications (4)

Application Number Title Priority Date Filing Date
TW103105419A TWI641602B (zh) 2013-02-20 2014-02-18 單環吡啶衍生物
TW107134529A TWI672140B (zh) 2013-02-20 2014-02-18 單環吡啶衍生物
TW107134522A TWI672296B (zh) 2013-02-20 2014-02-18 單環吡啶衍生物
TW107134526A TWI672139B (zh) 2013-02-20 2014-02-18 單環吡啶衍生物

Family Applications After (3)

Application Number Title Priority Date Filing Date
TW107134529A TWI672140B (zh) 2013-02-20 2014-02-18 單環吡啶衍生物
TW107134522A TWI672296B (zh) 2013-02-20 2014-02-18 單環吡啶衍生物
TW107134526A TWI672139B (zh) 2013-02-20 2014-02-18 單環吡啶衍生物

Country Status (35)

Country Link
US (1) US8933099B2 (de)
EP (1) EP2960238B1 (de)
JP (2) JP5600229B1 (de)
KR (1) KR102050128B1 (de)
CN (1) CN105073730B (de)
AR (1) AR094812A1 (de)
AU (1) AU2014219811B2 (de)
BR (1) BR112015019790B1 (de)
CA (1) CA2901585C (de)
CL (1) CL2015002311A1 (de)
CY (1) CY1119220T1 (de)
DK (1) DK2960238T3 (de)
ES (1) ES2628495T3 (de)
HR (1) HRP20170873T1 (de)
HU (1) HUE032931T2 (de)
IL (1) IL240623B (de)
JO (1) JO3261B1 (de)
LT (1) LT2960238T (de)
ME (1) ME02755B (de)
MX (1) MX361870B (de)
MY (1) MY178760A (de)
NZ (1) NZ711101A (de)
PE (1) PE20151509A1 (de)
PH (1) PH12015501813A1 (de)
PL (1) PL2960238T3 (de)
PT (1) PT2960238T (de)
RS (1) RS56064B1 (de)
RU (1) RU2645352C2 (de)
SG (1) SG11201506488WA (de)
SI (1) SI2960238T1 (de)
SM (1) SMT201700288T1 (de)
TW (4) TWI641602B (de)
UA (1) UA116794C2 (de)
WO (1) WO2014129477A1 (de)
ZA (1) ZA201505941B (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016027781A1 (ja) * 2014-08-18 2016-02-25 エーザイ・アール・アンド・ディー・マネジメント株式会社 単環ピリジン誘導体の塩およびその結晶
CN114984013A (zh) 2015-03-25 2022-09-02 国立癌症研究中心 胆管癌治疗剂
AU2016374441B2 (en) * 2015-12-17 2021-10-21 Eisai R&D Management Co., Ltd. Therapeutic agent for breast cancer
CN107098884A (zh) * 2016-02-19 2017-08-29 中国科学院上海药物研究所 一类取代的氨基吡啶类化合物及其制备和用途
CN111050768A (zh) * 2017-10-12 2020-04-21 卫材R&D管理有限公司 包含fgfr选择性酪氨酸激酶抑制剂的药物组合物
BR112020017922A2 (pt) 2018-03-28 2020-12-22 Eisai R&D Management Co., Ltd. Agente terapêutico para carcinoma hepatocelular
CA3129665A1 (en) 2019-03-21 2020-09-24 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
KR20220098759A (ko) 2019-11-08 2022-07-12 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 키나제 억제제에 대해 내성을 획득한 암의 치료 방법
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
WO2021210636A1 (ja) 2020-04-17 2021-10-21 エーザイ・アール・アンド・ディー・マネジメント株式会社 乳がん治療剤
US20230172924A1 (en) * 2020-07-31 2023-06-08 Eisai R&D Management Co., Ltd. Therapeutic agent for breast cancer
WO2022092085A1 (ja) 2020-10-28 2022-05-05 エーザイ・アール・アンド・ディー・マネジメント株式会社 腫瘍治療用医薬組成物
JP2023099778A (ja) * 2021-08-31 2023-07-13 エーザイ・アール・アンド・ディー・マネジメント株式会社 単環ピリジン誘導体の製造方法
IL310338A (en) * 2021-08-31 2024-03-01 Eisai R&D Man Co Ltd Production method for synthetic intermediate of monocyclic pyridine derivative
EP4361143A4 (de) * 2021-08-31 2025-05-28 Eisai R&D Management Co., Ltd. Verfahren zur herstellung eines monocyclischen pyridinderivats
WO2023174400A1 (zh) * 2022-03-18 2023-09-21 上海润石医药科技有限公司 一种取代的氨基六元氮杂环类化合物的盐及其晶型、制备方法和应用
AU2024345848A1 (en) * 2023-09-18 2026-04-09 Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences Pharmaceutical composition containing heteroaryl oxynaphthalene compound, preparation method therefor, and use thereof
WO2026004897A1 (en) * 2024-06-27 2026-01-02 Eisai R&D Management Co., Ltd. Method for predicting likelihood of response of human subject having tumor

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200413353A (en) * 2002-08-30 2004-08-01 Eisai Co Ltd Azaarene derivatives

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10006139A1 (de) * 2000-02-11 2001-08-16 Merck Patent Gmbh Indol-3-yl-Derivate
KR100600550B1 (ko) 2000-10-20 2006-07-13 에자이 가부시키가이샤 질소 함유 방향환 유도체
EP1375465A4 (de) 2001-04-03 2006-01-11 Eisai Co Ltd Cyclooctanonderivat und cyclodecanonderivat und deren verwendung
US20030187026A1 (en) * 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
US7098332B2 (en) 2002-12-20 2006-08-29 Hoffmann-La Roche Inc. 5,8-Dihydro-6H-pyrido[2,3-d]pyrimidin-7-ones
CA2521124A1 (en) 2003-04-10 2004-10-21 F. Hoffmann-La Roche Ag Pyrimido compounds
US20050256154A1 (en) 2004-05-04 2005-11-17 Kin-Chun Luk 4-Amino-thieno[3,2-c]pyridine-7-carboxylic acid amides
GB0512324D0 (en) 2005-06-16 2005-07-27 Novartis Ag Organic compounds
FR2883286B1 (fr) 2005-03-16 2008-10-03 Sanofi Aventis Sa NOUVEAUX DERIVES D'IMIDAZO[1,5-a]PYRIDINES, INHIBITEURS DE FGFs, LEUR PROCEDE DE PREPARATION ET LES COMPOSITIONS PHARMACEUTIQUES LES CONTENANT
EP2270000B1 (de) * 2005-05-23 2015-07-29 Novartis AG Kristalline und andere Formen von 4-Amino-5-Fluor-3-[6-(Methylpiperazin-1-yl)-1H-Benzimidazol-2-yl]-1H-Chinolin-2-on-Milchsäuresalz
ME00011A (me) 2005-12-21 2009-02-10 Novartis Ag Derivati pirimidinilaril uree kao fgf inhibitori
JP2009184924A (ja) 2006-05-31 2009-08-20 Eisai R & D Management Co Ltd 生物学的試薬用化合物
TW200811134A (en) 2006-07-12 2008-03-01 Irm Llc Compounds and compositions as protein kinase inhibitors
EP1891955A1 (de) 2006-07-24 2008-02-27 Sanofi-Aventis Verwendung von 1,2,3-subsituierte Indolizine, Hemmer von FGF, zur Herstellung eines Arzneimittels für die Behandlung von degenerativen Gelenkerkrankungen
US7737149B2 (en) 2006-12-21 2010-06-15 Astrazeneca Ab N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2H-pyrazol-3-yl]-4-(3,5-dimethylpiperazin-1-yl)benzamide and salts thereof
JP5442449B2 (ja) 2006-12-22 2014-03-12 アステックス、セラピューティックス、リミテッド 新規化合物
CN101679408B (zh) 2006-12-22 2016-04-27 Astex治疗学有限公司 作为fgfr抑制剂的双环杂环化合物
US8131527B1 (en) 2006-12-22 2012-03-06 Astex Therapeutics Ltd. FGFR pharmacophore compounds
CA2690368A1 (en) 2007-06-25 2008-12-31 Qinetiq Limited Heater suitable for use in a preconcentrator device
WO2009019518A1 (en) 2007-08-09 2009-02-12 Astrazeneca Ab Pyrimidine compounds having a fgfr inhibitory effect
GB0720041D0 (en) 2007-10-12 2007-11-21 Astex Therapeutics Ltd New Compounds
GB0720038D0 (en) 2007-10-12 2007-11-21 Astex Therapeutics Ltd New compounds
WO2009056886A1 (en) 2007-11-01 2009-05-07 Astrazeneca Ab Pyrimidine derivatives and their use as modulators of fgfr activity
CL2008003675A1 (es) * 2007-12-13 2009-03-20 Wyeth Corp Compuestos derivados de 5-alquil o alquenil 3-cianopiridinas, procedimiento de preparacion, composicion farmaceutica, util para reducir la actividad incrementada de una enzima en un mamifero, en donde dicha enzima es una proteina quinasa, destinado al tratamiento de la inflamacion, asma, colitis, esclerosis multiple, soriasis, artritis reumatoide.
WO2009076660A2 (en) * 2007-12-13 2009-06-18 Tyratech, Inc. Organic absorbent material and uses thereof
AU2009248774B2 (en) 2008-05-23 2012-05-31 Novartis Ag Derivatives of quinolines and quinoxalines as protein tyrosine kinase inhibitors
GB0810902D0 (en) 2008-06-13 2008-07-23 Astex Therapeutics Ltd New compounds
CA2728063A1 (en) 2008-06-19 2009-12-23 Astrazeneca Ab Pyrazole compounds 436
TW201036614A (en) 2008-12-30 2010-10-16 Arqule Inc Substituted 1H-pyrazolo[3,4-d]pyrimidine-6-amine compounds
CN102325755B (zh) 2008-12-30 2015-07-01 艾科尔公司 取代的5,6-二氢-6-苯基苯并[f]异喹啉-2-胺化合物
WO2010078427A1 (en) 2008-12-30 2010-07-08 Arqule, Inc. Substituted pyrazolo [3, 4-b] pyridine compounds
US9002427B2 (en) 2009-03-30 2015-04-07 Lifewave Biomedical, Inc. Apparatus and method for continuous noninvasive measurement of respiratory function and events
GB0906472D0 (en) 2009-04-15 2009-05-20 Astex Therapeutics Ltd New compounds
GB0906470D0 (en) 2009-04-15 2009-05-20 Astex Therapeutics Ltd New compounds
EP2270043A1 (de) 2009-07-03 2011-01-05 Sanofi-Aventis Extrazelluläre allosterische Inhibitorbindungsdomäne aus einem Tyrosinkinaserezeptor
FR2947546B1 (fr) 2009-07-03 2011-07-01 Sanofi Aventis Derives de pyrazoles, leur preparation et leur application en therapeutique
HRP20151258T1 (hr) 2009-08-07 2016-02-26 Chugai Seiyaku Kabushiki Kaisha Derivat aminopirazola
ES2524548T3 (es) 2009-10-30 2014-12-10 Novartis Ag N-óxido de 3-(2,6-dicloro-3,5-dimetoxi-fenil)-1-{6-[4-(4-etil-piperacin-1-il)-fenilamino]-pirimidin-4-il}-1-metil-urea
AR079257A1 (es) 2009-12-07 2012-01-04 Novartis Ag Formas cristalinas de 3-(2,6-dicloro-3-5-dimetoxi-fenil)-1-{6-[4-(4-etil-piperazin-1-il)-fenil-amino]-pirimidin-4-il}-1-metil-urea y sales de las mismas
GB201007286D0 (en) 2010-04-30 2010-06-16 Astex Therapeutics Ltd New compounds
FR2962437B1 (fr) 2010-07-06 2012-08-17 Sanofi Aventis Derives d'imidazopyridine, leur procede de preparation et leur application en therapeutique
GB201020179D0 (en) 2010-11-29 2011-01-12 Astex Therapeutics Ltd New compounds
WO2012088266A2 (en) 2010-12-22 2012-06-28 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
EP2548877A1 (de) * 2011-07-19 2013-01-23 MSD Oss B.V. 4-(5-Gliedrige kondensierte Pyridinyl)benzamide als BTK-Inhibitoren
GB201118652D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118654D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118656D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118675D0 (en) 2011-10-28 2011-12-14 Astex Therapeutics Ltd New compounds
FR2984325A1 (fr) 2011-12-14 2013-06-21 Sanofi Sa Derives de pyrazolopyridine, leur procede de preparation et leur application en therapeutique
AU2013210403B2 (en) 2012-01-19 2016-01-14 Taiho Pharmaceutical Co., Ltd. 3,5-disubstituted alkynylbenzene compound and salt thereof
UA114501C2 (uk) 2012-02-28 2017-06-26 Астеллас Фарма Інк. Азотовмісна ароматична гетероциклічна сполука
GB201209609D0 (en) 2012-05-30 2012-07-11 Astex Therapeutics Ltd New compounds
CA2876689C (en) 2012-06-13 2022-04-26 Incyte Corporation Substituted tricyclic compounds as fgfr inhibitors
NZ703495A (en) 2012-07-11 2018-02-23 Blueprint Medicines Corp Inhibitors of the fibroblast growth factor receptor
US9388185B2 (en) 2012-08-10 2016-07-12 Incyte Holdings Corporation Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
WO2014044846A1 (en) 2012-09-24 2014-03-27 Evotec (Uk) Ltd. 3-(aryl- or heteroaryl-amino)-7-(3,5-dimethoxyphenyl)isoquinoline derivatives as fgfr inhibitors useful for the treatment of proliferative disorders or dysplasia
WO2014048878A1 (en) 2012-09-26 2014-04-03 Evotec (Uk) Ltd. Phenyl- or pyridyl- pyrrolo[2,3b]pyrazine derivatives useful in the treatment or prevention of proliferative disorders or dysplasia
EA031631B1 (ru) 2012-09-27 2019-01-31 Чугаи Сеияку Кабушики Каиша Способ лечения или предупреждения злокачественного новообразования, способ отбора пациента, способ тестирования предрасположенности к злокачественному новообразованию у субъекта, гибридный полипептид и его применения
TWI628176B (zh) 2013-04-04 2018-07-01 奧利安公司 蛋白質激酶抑制劑

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200413353A (en) * 2002-08-30 2004-08-01 Eisai Co Ltd Azaarene derivatives

Also Published As

Publication number Publication date
IL240623A0 (en) 2015-10-29
JP2014237707A (ja) 2014-12-18
ZA201505941B (en) 2016-07-27
JP5600229B1 (ja) 2014-10-01
EP2960238A4 (de) 2016-08-17
TWI672296B (zh) 2019-09-21
TW201902889A (zh) 2019-01-16
PT2960238T (pt) 2017-06-05
TWI672139B (zh) 2019-09-21
ME02755B (de) 2018-01-20
MY178760A (en) 2020-10-20
RU2015134558A (ru) 2017-03-24
TW201900168A (zh) 2019-01-01
BR112015019790B1 (pt) 2020-12-01
NZ711101A (en) 2018-08-31
WO2014129477A1 (ja) 2014-08-28
KR102050128B1 (ko) 2019-11-28
MX2015010698A (es) 2016-04-11
EP2960238B1 (de) 2017-04-05
BR112015019790A2 (pt) 2017-07-18
AU2014219811A1 (en) 2015-09-03
TW201900169A (zh) 2019-01-01
JO3261B1 (ar) 2018-09-16
IL240623B (en) 2019-03-31
JPWO2014129477A1 (ja) 2017-02-02
KR20150118151A (ko) 2015-10-21
HUE032931T2 (en) 2017-11-28
CA2901585A1 (en) 2014-08-28
PH12015501813A1 (en) 2015-12-07
ES2628495T3 (es) 2017-08-03
DK2960238T3 (en) 2017-06-26
SG11201506488WA (en) 2015-09-29
SI2960238T1 (sl) 2017-07-31
CA2901585C (en) 2019-09-24
PE20151509A1 (es) 2015-10-18
HRP20170873T1 (hr) 2017-09-08
CY1119220T1 (el) 2018-02-14
EP2960238A1 (de) 2015-12-30
LT2960238T (lt) 2017-07-10
HK1215949A1 (en) 2016-09-30
TWI672140B (zh) 2019-09-21
US20140235614A1 (en) 2014-08-21
US8933099B2 (en) 2015-01-13
CN105073730A (zh) 2015-11-18
UA116794C2 (uk) 2018-05-10
SMT201700288T1 (it) 2017-07-18
RU2645352C2 (ru) 2018-02-21
CN105073730B (zh) 2017-10-13
AR094812A1 (es) 2015-08-26
PL2960238T3 (pl) 2017-09-29
RS56064B1 (sr) 2017-10-31
MX361870B (es) 2018-12-18
CL2015002311A1 (es) 2016-02-05
AU2014219811B2 (en) 2017-09-28
TW201439085A (zh) 2014-10-16

Similar Documents

Publication Publication Date Title
CN105073730B (zh) 单环吡啶衍生物
US10851092B2 (en) Pyridine compound
KR101985050B1 (ko) 피라진카르복사미드 화합물
JP6314147B2 (ja) 選択的ｐａｒｐ−１阻害剤としての４−カルボキサミド−イソインドリノン誘導体
KR20180041112A (ko) Cdk 억제제로서의 치환된 헤테로사이클릴 유도체
KR101562347B1 (ko) 시아노퀴놀린 유도체
HK40088780A (en) Pyrimidine compounds, their preparation methods and their medical use
HK40088780B (en) Pyrimidine compounds, their preparation methods and their medical use
HK40052813A (en) Pyridine salts and process
HK1215949B (en) Monocyclic pyridine derivative
EA051378B1 (ru) Ингибиторы parp1 и их применение